Bruker Corp (BRKR) is a global leader in scientific instruments manufacturing and analytical software development for molecular and materials research, diagnostic and applied analysis. Founded in 1960 by physicist Dr. Gunther Laukien, the company is headquartered in Billerica, Massachusetts.
Bruker Corp. operates in two segments: Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST). BSI provides innovative scientific instruments and analytical solutions to explore life and materials at molecular, cellular, and microscopic levels. It supports research in the areas like life sciences research, pharmaceuticals, biotechnology, agricultural and food safety, and forensics. It constitutes of three divisions; Bruker BioSpin, Bruker CALID, and Bruker Nano.
Meanwhile, the BEST segment develops and manufactures advanced superconductor materials, devices, and system solutions. It offers scientific instrumentation used for energy management, mobile power, transportation, and other technological research applications.
Publicly traded on the NASDAQ, Bruker Corp. is known for its high-performance scientific instruments and high-value analytical and diagnostic solutions that enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In addition, their instruments are used in a broad range of industries including pharmaceuticals, biotechnology, and commodities food testing, thus enhancing their customer base.
Over the decades, Bruker has carved a niche for itself with its innovative yet user-friendly solutions that have had a profound impact in the therapeutic and diagnostic market. The company has a strong presence worldwide with additional manufacturing, sales, and service facilities located throughout Europe, North America, and Asia.
In terms of innovations, Bruker is at the forefront of developing advanced technologies. They recently rolled out the world’s first 1.2 GHz high-resolution protein NMR (Nuclear Magnetic Resonance), which is an achievement in technology and performance.
In their annual report, the company consistently highlights its commitment to ethical business conduct and sustainable practices, valuing its global workforce composed of diverse talents as their driving force.
Bruker Corp has experienced continuous growth throughout the years, a testament to their commitment in delivering powerful, productive, and customer-oriented solutions that keep them at the leading edge of scientific research and related industries. It plays a pivotal role in improving the efficiency and effectiveness of the scientific process, accelerating scientific innovation, and enhancing the quality of life throughout the world.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
M&G PLC significantly reduced its stake in Bruker Corporation, selling 62.2% of its holdings in the third quarter but retaining 425,645 shares valued at $27.7 million. Despite the institutional selling, Bruker reported strong quarterly earnings of $0.56 EPS on revenue of $874 million, both exceeding analyst estimates. The stock, which has a "Moderate Buy" consensus rating from analysts, was up 8.5% and opened at $66.54.
Citigroup analysts have increased their price target for Bruker (NASDAQ:BRKR) to $64.00 from $53.00, maintaining a "hold" rating, suggesting a potential upside of 4.39%. This update comes alongside other analyst adjustments, resulting in an average "Moderate Buy" rating and a $60.57 price target for the company. Bruker recently reported strong quarterly earnings, beating analyst estimates with $0.56 EPS on revenues of $874.00 million.
Bruker Corporation announced it will report its third-quarter 2026 financial results before market opening on Wednesday, November 4, 2026. The company will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time to discuss these results and current business trends. Investors can access the webcast and pre-register for the conference call through Bruker's investor relations website.
Bruker Corp (BRKR) shares recently fell 4.4% to $56.25, placing it at a 6.9% undervaluation compared to its GF Value™ of $60.43. Despite a "Strong" GF Score™ of 83/100, indicating good overall performance with strong momentum and reasonable valuation, the company faces concerns due to its unprofitability, negative cash flow, and $3.6M in insider selling over the past year. Investors are advised to weigh these conflicting signals carefully, considering both the guru interest and the company's financial vulnerabilities.
Bruker Corporation (BRKR) has seen its shares rise 66.3% over the past year, driven by strong demand in biopharma, security detection, molecular diagnostics, and mass spectrometry, as well as growth in its preclinical imaging portfolio. Despite a significant non-cash goodwill impairment in Q2 2026 and sensitivity to exchange-rate changes, the company maintains healthy fundamentals and solid growth opportunities. Analysts' consensus estimate for 2026 EPS remains unchanged at $2.12, with an estimated long-term EPS growth rate of 15.4%.
Bruker Corporation has seen its shares rise by 66.3% over the past year, driven by strong demand in biopharma, diagnostics, and mass spectrometry, with significant revenue growth in its CALID businesses. Despite facing challenges like a $134.9 million goodwill impairment and currency pressures, the company's solid solvency and preclinical imaging portfolio contribute to its positive outlook. Analysts predict full-year 2026 revenues between $3.54 billion and $3.57 billion.